MICHELLE WORTHEN: Open Payments
NPI 1972177996 · TALLAHASSEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$596 in 25 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $596
Food & beverage: $516Education: $80
| Company | Payments | Amount |
|---|---|---|
| Exelixis Inc. | 1 | $80 |
| E.R. Squibb & Sons, L.L.C. | 3 | $56 |
| Stemline Therapeutics Inc. | 2 | $53 |
| Novartis Pharmaceuticals Corporation | 3 | $50 |
| Eisai Inc. | 2 | $45 |
| Janssen Biotech, Inc. | 2 | $41 |
| JAZZ PHARMACEUTICALS INC. | 1 | $39 |
| GENZYME CORPORATION | 1 | $31 |
| Genentech USA, Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
Products named: OPDIVO, Orserdu, Lenvima, RYBREVANT, ZEPZELCA, SCEMBLIX, AYVAKIT, Polivy.
Industry payments across FL — which companies pay providers there.
